Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclosporine
Drug ID BADD_D00551
Description Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_.[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Indications and Usage Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy[L3002] and to prevent or treat graft-versus-host disease (GVHD).[L11097] Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone.[L3734] It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.[L3734] The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca.[L11097] In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.[L11097] A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.[L34694] Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.[A139,A174085,A189393,A189396,A189399]
Marketing Status approved; investigational; vet_approved
ATC Code S01XA18; L04AD01
DrugBank ID DB00091
KEGG ID D00184
MeSH ID D016572
PubChem ID 5280754
TTD Drug ID D0O3YF
NDC Product Code 10888-5040; 11014-0033; 11014-0034; 11014-0041; 51927-0160; 55361-0025; 55361-0023; 23155-838; 0172-7313; 64380-127; 64380-128; 68084-921; 51927-3196; 55486-1567; 55486-1604; 55500-0009; 0093-9020; 51862-460; 60505-0134; 64380-129; 65086-001; 0574-0866; 47848-004; 51552-0663; 59573-0001; 66507-0001; 0074-3108; 0078-0241; 23155-837; 23155-839; 47335-506; 60505-0133; 0378-8760; 65897-3008; 0078-0110; 60505-4630; 60505-4632; 63629-8640; 65897-1008; 0078-0246; 0078-0274; 0093-9019; 68084-879; 11014-0040; 51927-0213; 55361-0022; 55361-0026; 68254-2501; 0078-0248; 47335-507; 60505-4631; 60505-6202; 68180-214; 10888-5041; 52928-005; 52972-0027; 55486-1602; 10702-808; 68254-0008; 0074-3109; 0074-7269; 0078-0109; 0078-0240; 0023-5301; 0074-5503; 51862-458; 55486-1603; 0093-9018; 0023-9163
UNII 83HN0GTJ6D
Synonyms Cyclosporine | Cyclosporine A | Cyclosporin A | Ciclosporin | Cyclosporin | Neoral | Sandimmun Neoral | CyA-NOF | CyA NOF | Sandimmune | Sandimmun | CsA-Neoral | CsA Neoral | CsANeoral | OL 27-400 | OL 27 400 | OL 27400
Chemical Information
Molecular Formula C62H111N11O12
CAS Registry Number 59865-13-3
SMILES CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C (C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C C(C)C)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Brain oedema12.01.10.010; 17.07.02.0030.000221%
Emotional distress19.04.02.008--Not Available
Onychomadesis23.02.05.0060.000111%
Lip blister23.03.01.016; 07.05.01.007--Not Available
Shock haemorrhagic14.05.05.003; 24.06.02.0140.000221%Not Available
Pneumomediastinum22.09.03.0040.000276%Not Available
Intervertebral disc protrusion15.10.01.0040.000276%Not Available
Scleral haemorrhage24.07.05.009; 06.07.01.0020.000376%Not Available
Ventricular hypokinesia02.04.02.0130.000111%Not Available
Eye naevus16.34.02.001; 06.12.02.0010.000111%Not Available
Foreign body sensation in eyes06.01.01.0060.009581%Not Available
Madarosis23.02.02.004; 06.06.04.0100.002254%Not Available
Central nervous system lesion17.02.10.0110.000553%Not Available
Post transplant lymphoproliferative disorder01.13.02.004; 16.21.02.004; 11.05.10.0060.000442%Not Available
Rhinalgia22.12.03.0200.000431%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Conjunctival hyperaemia06.04.01.0040.000243%Not Available
Eyelids pruritus23.03.12.005; 06.08.03.0070.001691%Not Available
Gastrointestinal hypomotility07.02.02.0050.000111%Not Available
Eyelid margin crusting23.03.03.029; 06.04.04.0050.001182%Not Available
Ear discomfort04.03.01.0050.000354%Not Available
Eye pruritus06.04.05.0060.014764%Not Available
Ocular discomfort06.08.03.0080.004431%Not Available
Lymphatic disorder01.09.01.003--Not Available
Systemic mycosis11.03.05.012--Not Available
Wound23.03.11.043; 12.01.08.009--Not Available
Nasal discomfort22.12.03.0120.000376%Not Available
Oral pruritus07.05.05.002--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 28 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene